BRCA1 and BRCA2 mutations are estimated to be responsible for the great majority of familial breast and ovarian cancers. Much progress has been made toward the understanding of the function of these proteins through genetic, biochemical, and structural studies. The embryonic lethality encountered in the knockout mouse initially hindered the development of mouse models aimed at studying tumor suppression. However, mice that harbor hypomorphic Brca1 and Brca2 alleles and cre-mediated tissue-specific deletions for Brca1 and Brca2 have been generated. Mice deficient for either Brca1 or Brca2 sustain a wide range of carcinoma and mammary epithelium deleted for Brca1 or Brca2 is highly susceptible to mammary tumorigenesis. Mammary (and other) tumors occur at long latency as compared to oncogene-induced mouse tumors. p53 deficiency is highly cooperative with both Brca1 and Brca2 in promoting tumorigenesis. Analysis of Brca1-associated mammary tumors reveals significant similarities to BRCA1-associated breast cancer in regard to high tumor grade, hormone receptor negativity, a high incidence of p53 mutations and genetic instability.
Introduction
Tumor suppression by BRCA1, located on chromosome 17q21, was established by linkage analysis of human cancer families, prior to positional cloning of the gene (Easton et al., 1993; Hall et al., 1990; Miki et al., 1994) . A similar, albeit more expeditious, approach was used to identify the BRCA2 tumor suppressor on chromosome 13q12 (Wooster et al., 1994) . The observation that BRCA1 and BRCA2 form nuclear foci with Rad51 during S phase and following DNA damage was the key to forming a link with DNA repair Scully et al., 1997) . Repair assays of Brca1 and Brca2 mutant cells confirmed defects in the homologous repair of chromosomal double-strand breaks (DSBs) (Moynahan et al., 1999 (Moynahan et al., , 2001b . Homologous recombination is a fundamental cellular process for generating diversity during meiosis and precise repair of chromosomal breaks in mitotic cells; therefore, it was somewhat disquieting that homologs were not identified in yeast. The recent observations that homologs of particularly conserved domains of BRCA1 and BRCA2 are found in lower eukaryotes suggest that the functions of these proteins are fundamental for genomic stability (reviewed by Jasin, current issue).
Although BRCA1 and BRCA2 are both involved in homology-directed repair (HDR), BRCA1 appears omnipresent with a wealth of biochemical data describing multi-protein interactions (Welcsh and King, 2001 ). BRCA1 has a broader role in cellular functions than BRCA2, despite a similarity in cellular phenotype. Functions ascribed to BRCA1 include transcriptional regulation that includes both p53-dependent and independent responses (MacLachlan et al., 2002; Monteiro, 2002; Welcsh et al., 2002) , ubiquitin ligase activity when dimerized to BARD1 (Baer and Ludwig, 2002) , and damage associated phosphorylation of BRCA1 by multiple kinases that precedes repaircomplex formation (Cortez et al., 1999; Lee et al., 2000; Tibbetts et al., 2000) . The function of BRCA2 appears more straightforward; BRCA2 is central to HDR repair through BRC-mediated Rad51 interactions and direct binding to single-stranded DNA (Davies et al., 2001; Yang et al., 2002) .
A precise determination as to the function most likely to safeguard against tumorigenesis is not yet proven. One common hypothesis relates to a striking phenotype, genetic instability, which is observed in cells deficient in BRCA1 or BRCA2 as well as in cells mutant for any gene involved in the homologous repair of DSBs. This instability manifests as spontaneous chromosome aberrations and hypersensitivity to agents that produce DNA DSBs such as ionizing radiation and interstrand cross-linking agents (reviewed in Jasin, current issue). Although genetic instability is observed in most human solid tumors, the rapidity with which cells deficient for Brca1 and Brca2 accumulate chromosomal aberrations is striking (Turner et al., 2002; Tutt et al., 2002; Xu et al., 2001b) , and the extent of chromosomal aberrations in Brca1-associated mammary tumors exceeds that of oncogene-induced tumors (Weaver et al., 2002) . That accumulating genetic change, in the form of chromosomal aberra-tions and resultant loss and gain of function of other genes, is the trigger for BRCA-associated tumorigenesis is supported by animal models with late-onset tumorigenesis, tumor multiclonality and relatively few cancers arising per cell at risk. These mouse models of tumorigenesis and their parallels to human BRCA1 and BRCA2-associated tumorigenesis will be reviewed.
Mouse models and Brca-associated tumorigenesis

Brca1
Deficiency of Brca1 results in early embryonic lethality in the majority of mutations predicted to result in protein truncations that delete the C-terminal half of the protein ). Mid-embryonic lethality was noted in the Brca1 D223-763 and Brca1
D11
embryos which express a Brca1 splice product that deletes exon 11 but maintains the N-terminal RING domain and the C-terminal BRCT repeats and in the Brca1 1700T embryos which express a Brca1 product truncated in the C-terminus before the second BRCT repeat Hohenstein et al., 2001) . p53 mutation extended embryonic viability in the Brca1 null mice by 1 -2 days and permitted live births in mice that express the Brca1 exon 11 deleted splice product (Cressman et al., 1999a; Xu et al., 2001b) (Table 1 ; Figure 1 ).
Prolonged breeding of Brca1 D223-763/+ and p53
heterozygote mutant mice resulted in three viable homozygous double knockout mice that survived to adulthood. These mice had severe growth defects and acquired thymic lymphomas and a hemangiosarcoma, tumors typical of p53 7/7 mice (Cressman et al., 1999a) . Tumor latency and life span were decreased in the homozygous double knockout as compared to p53 7/7 mice. Interestingly, post-natal viability was accomplished in the Brca1 D11/D11 mice by Brca1 cre-mediated deletion in germ cells by crossing Brca1 flox11 mice with EIIA-cre mice (Xu et al., 2001b) . The cre-mediated Brca1 D11/D11 deleted mice had 1% viability; however, further details regarding the life span and development of the few animals that survived were not reported. Crossing to p53 7/7 and p53 +/7 mice resulted in near complete rescue of viability. Twenty-two female Brca1
+/7 mice were followed, with most developing mammary carcinoma at a latency of 6 -10 months. Additionally, in this group of mice, seven lymphomas and two ovarian carcinomas were identified.
Recently, a viable Brca1-deficient homozygous mouse (Brca1 Tr/Tr ) line was generated on both 129/Sv and 129/Sv/MF1 genetic backgrounds; whereas the same mutation generated on the C57Bl/6 genetic background resulted in embryonic lethality (Ludwig et al., 2001a) . The 50 bp exon 11 insertion was predicted to result in a truncated product at amino acid 924; however, the truncated transcript could not be detected. There was no detectable full-length Brca1 product, but the endogenous Brca1 splicing variant lacking exon 11 was expressed at wild-type levels. Typically, this splice variant is weakly expressed. Like the Brca1 D223-763/D223-763 /p53 7/7 mice, Brca1 Tr/Tr males were infertile. A wide spectrum of tumors arose in both male and female adult Brca1
Tr/Tr mice at a significant frequency (85%), with the majority occurring in mice with an MF1 genetic background. This was significantly different from the 26% incidence of spontaneous tumors in the control mice. Lymphoma occurred with variable latency, ranging from 1 -24 months, whereas non-lymphoid tumors began occurring after 9 months, with an average latency of 18 months for all nonlymphoid cancers and a 15-month breast-cancerspecific latency. Carcinomas of multiple epithelial tissues occurred; most common were mammary and lung, but also included endometrial and colon. In addition, sarcomas, hepatocellular carcinomas and adenomas were observed. As with the Brca1
7/7 mice, the double knockouts of Brca1
Tr/ Tr /p53 7/7 resulted in a shorter life span and decreased tumor latency as compared to p53 7/7 single mutant mice (Cressman et al., 1999a) .
Developmental analysis in the Brca1 D223-763/D223-763 / p53 7/7 was notable for male infertility with defective spermatogenesis. Visceral development appeared normal. However, developmental abnormalities were noted in the epithelium of mammary, parotid, and prostate glands. Mammary development was the most significantly altered, with decreased ductal branching, fewer primary ducts, and underdeveloped end-bud formation. Fewer developmental defects were observed in the parotid and prostate gland, but the findings were notable for atrophy of salivary acinar epithelium and cytomegaly in both glands. Skin abnormalities were also apparent with alopecia, graying, and atrophy of dermal appendages (Cressman et al., 1999a) . In the female Brca1 D11/D11 /p53 +/7 and the Brca1 Tr/Tr mice, normal mammary gland development was reported (Ludwig et al., 2001a; Xu et al., 2001b) .
Brca2
Similar to Brca1, Brca2 deficiency results in early embryonic lethality in the mouse when disrupting mutations produce truncations that occur 5' to exon 11 (Ludwig et al., 1997; Sharan et al., 1997) . However, partial viability is obtained when a truncated Brca2 product retains Rad51 interacting BRC repeat sequences (Connor et al., 1997; Friedman et al., 1998) . The Brca2 tm1Cam and Brca2 Tr2014 homozygous mice have mutations that result in partial viability with truncating Brca2 mutations occurring within the BRC repeat domain. These mice had similar phenotypes. All succumb to thymic lymphoma with markedly decreased life spans. Both males and females are infertile (Table 2; Figure 2 ).
Brca2 mutant mice that lack exon 27, the Brca2 D27/D27 , have been recently reported (McAllister et al., 2002) . These mice have a subtle degree of embryonic/peri-natal lethality, appear developmentally normal, and have a shortened life span. The shortened life span was determined to be related to an increase in tumorigenesis. Overall, there was a modest 2.5-fold increase in the incidence of spontaneous tumorigenesis with tumors occurring in 61% of the Brca2 D27/D27 mice as compared to 24% of heterozygote and wild-type mice. Similar to the Brca1
Tr/Tr mice, a wide spectrum of tumors was observed including carcinomas, lymphomas, sarcomas, and adenomas. Most notable was the finding that carcinoma only arose in the mutant Brca2 D27/D27 mice (11 tumors in nine mice out of 41 analysed), whereas no carcinomas occurred in the heterozygote or wild-type mice. The 22% incidence of carcinoma occurred in mammary, gastric, endometrial, and lung epithelial cells. There was long tumor latency, with tumors occurring in the 12th to 17th month and only one-third of the tumors were detected prior to animal sacrifice.
Although mammary tissue was not highly susceptible to tumorigenesis, this observation may be due to the 129/C57Bl/6 genetic background as these strains rarely develop spontaneous or carcinogen-induced mammary carcinogenesis (Kuperwasser et al., 2000) . Supporting this hypothesis is the Brca1
Tr/Tr mouse model, discussed above, where tumors were predominantly seen on the 129/Sv/MF1 outbred genetic background as compared to the 129/Sv strain (Ludwig et al., 2001a) . Analysis of mammary development in the Brca2
mice was notable for a dramatic increase in ductal side branching and an overall decreased density of ducts. However dams were able to nurse their pups despite diminished development of the mammary gland.
Tumorigenesis in conditional Brca1 and Brca2 mutations
Several mouse models have been created which mutate either Brca1 or Brca2 by cre-mediated recombination in specific tissues. Brca1 and Brca2 deletion restricted to mammary epithelium was achieved using the highly restricted WAP (whey acidic protein) promoter and the somewhat less specific MMTV-LTR (mouse mammary tumor virus-long terminal repeat) to direct expression of cre (Ludwig et al., 2001b; Xu et al., 1999a) . In addition, mouse models with tissue-restricted cremediated deletion of Brca1 in thymocytes directed by the Lck promoter and of Brca2 exon 11 in epithelium directed by the human keratin 14 (K14) gene promoter were generated (Jonkers et al., 2001; Mak et al., 2000) ( Table 3) .
All three models that delete Brca1 or Brca2 in mammary epithelium sustain mammary tumors.
However, mammary tumorigenesis in the K14cre/ Brca2 F11/F11 mice was dependent on the loss of p53 (Jonkers et al., 2001 ). An important feature to keep in mind in these conditional animal models is that cremediated deletion of Brca1 or Brca2 is dependent on the activity of the promoter that is driving cre expression and can be quite variable. In addition, cre-mediated deletion is active only in the mammary epithelial cells and not in surrounding stromal tissue. Figure 1 Wild-type Brca1, the Brca1 mouse mutations and the predicted protein products. A 92kd exon 11 deleted Brca1 product is expressed in many of the mutant mouse models by alternative splicing. aa encoded by exon 11 are depicted in blue
In the Brca1 Ko/Co /Wap-cre and Brca1 Ko/Co /MMTV-cre mice, the extent of cre-mediated recombination was analysed during pregnancy when both promoters would be expected to be most active. Brca1 transcripts were variably decreased ranging from 10 -70% as compared to controls (Xu et al., 1999a) . In the Brca2 flox/7 /Wap-cre mice, reported by Ludwig et al., 32% of the alleles underwent cre-mediated recombination following the first pregnancy, however with subsequent pregnancies the presence of the floxed allele increased (Ludwig et al., 2001b) . In the K14cre/ Brca2 F11/F11 mice, expression of cre by the K14 promoter resulted in recombination in only 5 -30% of mammary epithelium (Jonkers et al., 2001) . The timing and strength of cre expression in the conditional models may significantly alter the incidence and latency of tumorigenesis as well as the potential for developmental abnormalities.
Analysis of mammary gland development in the Brca1
Ko/Co /MMTV-cre mice during pregnancy revealed incomplete ductal and alveolar development, with incomplete fat pad filling and increased apoptosis. The magnitude of the developmental defect was correlated to the amount of cre-mediated deletion, whereas those glands that had extensive apoptosis and filling of less than 50% of the fat pad had transcripts that were reduced by 60 -80%. Surprisingly, mothers were able to nurse their litters (Xu et al., 1999a) . No developmental defects were noted in the K14cre/ Brca2 F11/F11 or the Brca2 flox/7 /Wap-cre mice (Jonkers et al., 2001; Ludwig et al., 2001b) .
The first mouse model to directly demonstrate the tumor suppressor activity of Brca1 was reported by Xu et al., with the creation of the Brca1
Ko/Co /
MMTV-cre and Brca1
Ko/Co /Wap-cre mice which deletes exon 11 upon cre expression in mammary epithelium (Xu et al., 1999a) . As noted above, this deletion can be alternatively spliced, resulting in expression of an exon 11 deleted Brca1 product. The initial report on a small number of mice was notable for five mammary tumors occurring in 23 mice at a latency of 10 -13 months. Molecular analysis of the tumors revealed reduced intensity of the unrecombined Brca1 allele, suggesting that most of the cells had undergone cre-mediated deletion. Analysis of additional mice was reported in a followup study, confirming an incidence of mammary tumorigenesis of 25% in 150 mice followed over a 2-year period with an average tumor latency of 11 months . Generation of Brca1
Ko/Co / p53+/7 revealed both a striking increase in tumor incidence, from 25 to 100%, and a decrease in tumor latency. The number of mice with multifocal tumors or metastatic sites was not altered by p53 heterozygosity. Two Brca1
Co/Co mice and three Brca1 Co/Co /p53 +/7 mice had metastasis to lung, liver, and lymph node.
The first conditional knockout of Brca2 in mammary epithelium, Brca2 flox/7 /Wap cre mice, created a mutation in exons 3 and 4. Twenty-six experimental and 12 control multiparous female mice were analysed for mammary tumor formation over a 20-month period. Twenty out of 26 Brca2 flox/7 /Wap cre mice developed mammary tumors (77%), compared to no mammary tumor development in the control animals. Palpable tumors were first observed at 13 months. Analysis of the sacrificed mice revealed significant tumor multifocality, with 10 of the 20 mice having 2 -4 tumors (Ludwig et al., 2001b) . A second conditional mutation was created by cremediated deletion of Brca2 exon 11 (Jonkers et al., 2001) . The predicted Brca2 product would be devoid of the Rad51 interacting BRC domains in exon 11 but should retain N-terminal and C-terminal sequences that may possess other functional domains, such as DNA binding (Yang et al., 2002) . This mutation resulted in loss of essential Brca2 functions, as cre expression in the germ-line resulted in embryonic lethality. As noted above, the K14 promoter used in these mice to drive cre expression was weakly expressed in mammary epithelium. The K14cre/Brca2 F11/F11 female mice did not incur mammary tumors; however, breeding to p53 F2-10/F2-10 mice resulted in mammary tumors with an incidence of 77% for double-mutant mice and 55% for K14cre/Brca2 F11/F11 /p53 +F2-10 heterozygote mice. Additionally, Brca2 F11/+ /p53
F2-10/ F2-10 mice containing a wild-type Brca2 allele had a 31% incidence of mammary tumors. Confirmation that both p53 and Brca2 are tumor suppressors for breast cancer was shown by molecular analysis of the 21 Brca2
F2-10/F2-10 mammary tumors. All four conditional alleles had undergone cre-mediated deletion. However, in the Brca2 F11/+ / p53 F2-10/F2-10 mammary tumors, several had lost the wild-type and conditionally deleted Brca2 alleles, but nearly half had retained both alleles. The decreased incidence and increased latency of tumorigenesis observed in this conditional model, when only one of these tumor suppressor genes is mutated, supports the hypothesis that multiple genetic changes are required for Brca2-associated tumorigenesis. No significant metastatic potential was observed in the Brca2 flox/7 or Brca2 F11/F11 mice. Tumor suppression by Brca1 and Brca2 in the mouse appears to be a more general phenomenon than in humans, although predisposition to multiple cancers has been associated with Brca2 (discussed below). Carcinoma, lymphoma and sarcoma arose in the hypomorphic Brca2 ex27 and the Brca1 Tr mouse models. In the conditional models, the K14 promoter directs expression of cre in skin and salivary gland epithelium as well as upper alimentary tract epithelium and thymus. Squamous cell carcinoma of skin was frequently observed, as were rare salivary gland tumors. In the Lck-cre/Brca1 f5-6 T-cell specific deletion, a predisposition to thymoma was observed (Hakem and Mak, 2001 ).
Pathology of Brca-associated mouse mammary tumors
Several reports that have documented an increased predisposition to cancer in the Brca-deficient mouse models have provided detailed pathologic descriptions, assessments of genomic instability, and analysis of genes commonly associated with human breast cancers. The pathology of human BRCA1 and BRCA2-associated breast cancer reveals significant differences between the two types and in particular for BRCA1-associated breast cancers as compared to sporadic breast cancers (reviewed in Phillips, 2000) . Distinctive gene expression profiles for both BRCA1 and BRCA2 associated breast and ovary cancers have been reported (Hedenfalk et al., 2001; Jazaeri et al., 2002; van't Veer et al., 2002) . One significant purpose of mouse models of disease is to recapitulate the human disease process, as an understanding of the pathogenesis of the tumors arising from these mouse models may yield important biologic pathways and therapeutic strategies that can be extended to human disease prevention and treatment.
The pathology of human BRCA1-associated breast cancers is most commonly described as high grade, hormone-receptor negative, Her2 non-overexpressing infiltrating ductal adenocarcinomas. The initial description of the mammary tumors arising from the Brca1 Ko/Co conditional mouse model was of histologic diversity and genetic instability (Xu et al., 1999a) . The tumors arising from this model have undergone subsequent molecular analysis Weaver et al., 2002) . In addition, Ludwig et al. (2001a,b) have provided a comprehensive pathologic and immunohistochemical analysis on mammary tumors arising in both the Brca1
Tr mouse and the conditional Brca2 flox mouse.
Breast tumors arising in the Brca1
Tr mouse were notable for extremely heterogenous histologic patterns and variability in nuclear atypia. Both expansile and invasive tumors were observed. Immunohistochemical analysis for human breast cancer related genes were notable for uniformly positive expression of cyclinD1 and p21, whereas a majority of the cancers stained positive for p53 and negative for the Her2, estrogen and progesterone receptors (Ludwig et al., 2001a) . The follow-up study reporting on larger numbers of the conditionally deleted Brca1
Co mouse confirmed diverse histology, nuclear atypia, a high mitotic index and negative staining for the estrogen receptor . No histologic differences were noted to be attributable to tumors arising from a p53-deficient genetic background as compared to Brca1-deficiency alone.
A candidate gene analysis of Her2 (erbB2), cMyc and CyclinD1, was specifically undertaken, since these genes are often over-expressed and/or amplified in human breast cancers. Immunohistochemial (IHA) and/or Western blot analysis for expression was shown for nine Brca1
Co tumors, three of which were derived from the p53 +/7 cross ). All tumors were notable for demonstrable but variable expression of cyclinD1. The authors report over-expression of Her2 and cMyc in the majority of tumors; however, the evidence for over-expression by Western analysis was modest in most and quite variable. In human breast tumors, it has become clear that the degree to which Her2 is overexpressed is important for selecting those patients most likely to benefit from therapies directed against the Her2 pathway. Typically, only those patients who have intense (3+) Her2 immunostaining of HER2 gene amplification benefit from antiHer2 therapies (Seidman et al., 2001 ). Expression of cell cycle regulators was notably absent for p16 and present for cdc2, p21 (weak), and p27 expression.
BRCA2-associated human breast tumor and sporadic breast cancer have similar histology and immunohistochemical profiles, with a significant proportion being hormone receptor positive. However, BRCA2 breast tumors are more likely to be of moderate to high grade (Phillips, 2000) . Unlike Brca1-associated mouse mammary tumors, the Brca2-associated tumors were much less heterogenous. The Brca2 flox conditional mammary deletion gave rise to grossly palpable tumors, with only two histological patterns (solid carcinoma and adenosquamous carcinoma), with an occasional tumor containing both types (Ludwig et al., 2001b) . The tumor cells were uniform with mild nuclear pleomorphism, with the exception of two tumors that had significant nuclear atypia. IHA of the tumors revealed 50% estrogen receptor positive, greater than 90% progesterone receptor negative, 100% Her2 negative, 100% cyclinD1 positive, 100% p21 positive and 70% p53 positive. Sequence analysis of p53 was performed on five tumors, three of which contained point mutations.
Pathology from the mammary tumors arising in the K14cre/Brca2 F11/F11 /p53 F2-10/F2-10 female mice was notable for multiple in situ lesions, high nuclear grade, and an expansive growth pattern (Jonkers et al., 2001) . One difference in this conditional model, that is likely attributable to the cell specificity of the keratin 14 promoter, was that carcinoma arose in the myoepithelial/basal cell types. Basal epithelial and myoepithelial cells are typically positive for keratin 14 staining (Jones et al., 2001) . The most common type of tumor was a 'baseloid' carcinoma with a monomorphic cell type, and with pseudo-glandular and occasional squamous differentiation. Baseloid cancer is seen infrequently in humans. However it was recently reported to be a variant of adenoid cystic carcinoma with a propensity for lymph node metastases (Shin and Rosen, 2002 
Genomic instability
A phenotypic hallmark in cells mutated for genes involved in DNA double-strand break repair is spontaneous chromosome instability. Genetic instability is commonly observed in human tumors. However, in cells with defective chromosome break repair, this is an early and likely precipitating event. Dramatic chromosome aberrations were noted in Brca1 and Brca2-deficient embryonic tissue (Tutt et al., 2002; Xu et al., 2001b) and in cells deficient in Brca1 and Brca2 (Moynahan et al., 2001a; Shen et al., 1998; Turner et al., 2002; Tutt et al., 1999; Yu et al., 2000) .
Tumor cells were derived from six primary Brca2 flox tumors to assess for genetic instability by metaphase karyotype analysis. The tumor cells demonstrated various degrees of aneuploidy, chromosome aberrations, and fragments. Notably, the variability observed in chromosome instability did not give rise to varying histology (Ludwig et al., 2001b) . Three primary p53 +/7 / Brca1
Co/Co tumor cell lines were aneuploid with associated structural aberrations . The observed genomic instability in initial metaphase spreads was further investigated using a newer and more sensitive cytogenetic technique called spectral karyotyping (SKY) (Weaver et al., 2002) . This method uses multicolor chromosome paints, that can be used to more accurately assess chromosome aberrations and allow the identification of the chromosomes contributing to the rearrangements. Seven tumors (5-Brca1
Ko/Co and 2-p53
Ko/Co ) were analysed, six at early passage number. All the tumors displayed numerical and structural chromosome aberrations, including chromatid and chromosome breaks, insertions, deletions, and rearrangements. Two were largely clonal, whereas other tumors had different degrees of multiclonality, indicating ongoing genomic instability.
Comparative genomic hybridization (CGH) was used to evaluate chromosomal gains and losses in 11 Brca1
Ko/Co and four Brca1 Ko/Co /p53 +/7 mammary tumors (Weaver et al., 2002 ). An average of eight chromosome copy alterations/tumor genome were observed despite diverse histology. CGH performed on the Brca1
Ko/Co /p53 +/7 tumors revealed no increase in chromosomal instability above that observed for Brca1
Ko/Co tumors. This degree of genomic alteration is greater than that measured for oncogene-driven mouse mammary tumors, and in the range of that seen with aneuploid human breast cancers. The hypothesis that loss of BRCA functions results in genomic instability arising from unrepaired or misrepaired chromosomal breaks suggests that a random pattern of chromosome alterations might be observed. However, a pattern of non-random, recurring chromosome alterations was noted in the 15 Brca1 mammary tumors with a gain of distal chromosome 11 (9/15), a partial gain of chromosome 15 (8/15), loss of distal chromosome 14 (6/15), and gain of the X chromosome (4/15). Four of the 15 also had a loss of proximal chromosome 11, which is a region orthologous to human 17p and may include the p53 gene. Specific genes important in human carcinogenesis are mapped to these regions of chromosomal gain (chr 15-cMyc) and chromosomal loss (chr 14-Rb). Thus far, the pathology features and the genetic alterations observed in the Brca1
Co mouse mammary tumor appears to be a close, if not true, 'model' for human BRCA1-associated breast cancers and may yield important additional insights into this disease with further study.
Modifiers of tumorigenesis -the p53 gene
The embryonic lethality originally described in the Brca1 and Brca2 knockouts could be modulated by p53. Loss of p53 allowed the embryos to survive a day or two longer. This was thought to be due to both the abrogation of apoptosis and the relief from a proliferation block caused by p53-dependent p21 activation of the G1-S checkpoint. It is likely that unrepaired chromosome breaks that arise in proliferating cells trigger p53 activation. However, the activation and outcome of p53-dependent processes may be celltype dependent. Breeding of the Brca1 D11/+ mice to Bax 7/7 and Cdkn1a 7/7 mice could not rescue the lethality of Brca1 D11/D11 embryos, as did the cross to p53-deficient mice, which implies a role for multiple p53 pathways in the rescue of the Brca1-deficient embryos (Xu et al., 2001b) . However, restoration of the T-cell population in the conditionally deleted Lck-cre/ Brca1 f5-6 mouse occurred by intercross to either p53-deficient or Bcl-2 transgenic mice, but was not rescued by breeding to the Cdkn1a 7/7 mice (Mak et al., 2000) . The abrogation of one or both of these processes may be important in permitting tumorigenesis. As was noted in the Brca1 and Brca2 mouse models that have been crossed to p53-deficient mice, p53 loss accelerated tumor formation and increased tumor incidence. The effect of p53 heterozygosity was dramatic, with typically greater than a doubling of tumor incidence. A fourfold increase in mammary tumorigenesis was observed when the conditional Brca1
Co mouse was bred to a p53 heterozygote mouse, whereby the tumor incidence increased from 25 -100% and average tumor latency decreased by three months . The majority of tumors had lost the wild-type p53 allele. In both Brca1 D11/+ and Brca1 D223-763/+ mutations, p53-deficiency was required for post-natal survival of the Brca1 homozygous mutant mouse; therefore, the role of p53 in promoting tumorigenesis cannot be measured. The Brca1
Tr/Tr mouse mutation had a high incidence of tumorigenesis even in the absence of a p53 intercross; however, tumor latency was decreased by approximately 6 months in the Brca1
Tr/Tr /p53 +/7 mice (Ludwig et al., 2001a) . Mammary tumors occurred only with p53 deficiency in the K14-cre/Brca2 F11/F11 mice (Jonkers et al., 2001 ). In all tumors that arose in the Brca2 F11/F11 /p53 F2-F10 background the wild-type p53 allele had been lost. The effect of genetic p53-deficiency has not yet been reported for the conditional Brca2 flox mammary mutation or the Brca2 ex27 deleted mouse model. It will be of interest to see if the magnitude of the p53 effect with these mutations is as striking as those currently described.
Loss of wild-type p53 or positive p53 expression by immunohistochemical staining has been reported in the majority of Brca-associated mammary tumors analysed. However, this was not a universal finding and therefore cannot be considered a prerequisite, per se, to Brca-associated mouse mammary tumorigenesis. Positive immunostain for p53 expression assumes a p53 stabilizing point mutation. There is limited sequence analysis data to identify p53 point mutations. When it was examined in two studies, only 3/5 tumors examined confirmed a point mutation in p53 (Ludwig et al., 2001b; Weaver et al., 2002) .
The significance of p53 status in human BRCA1-associated breast cancer is difficult to ascertain. Some studies report that mutated TP53 is strongly associated with BRCA-associated breast cancer, whereas others have not found the frequency of p53 alterations to be different from that found in sporadic breast cancers as measured by IHA (Phillips, 2000) . TP53 is reported to be mutated in 20 -50% of sporadic breast cancer. However, other studies report that 85% of human breast cancers have p53 dysfunction as determined by the presence of TP53 allelic loss and/or p53 protein overexpression (Janocko et al., 2001) . A recent re-analysis of a data set of BRCA-associated breast cancers in comparison to control cancers revealed a complex pattern of p53 immunostaining. A similar percentage of all cancers were negative for p53 (39 -45%). However, more BRCA1 tumors demonstrated strong p53 immunoreactivity as measured by both intensity and number of cells stained (BRCA1, 34%; control, 16%) and fewer BRCA1 tumors demonstrated weak p53 immunostaining (BRCA1, 8%; control, 26%). BRCA2 breast cancers were not significantly different from control tumors for p53 immunostaining (Lakhani et al., 2002) .
A provocative early study demonstrated novel TP53 mutations arising in BRCA1-associated breast tumors (Crook et al., 1998) . Functional studies performed with these novel TP53 mutations revealed a separation of function where transactivation, checkpoint, and apoptosis remained intact. However, the mutants were unable to suppress transformation (Smith et al., 1999) . A recent analysis pooled data from p53 mutations reported in 12 studies in BRCA1 and BRCA2-associated breast cancer and compared the TP53 mutations in these cancers to those reported to the TP53 somatic mutation data base (Greenblatt et al., 2001) . Both p53 overexpression and TP53 mutation were significantly more frequent in BRCAassociated cancers than in sporadic cancers. However, out of 82 TP53 mutations, 58 were missense mutations, 19 of which had never been reported in breast cancer and nine had never been reported in any cancer, confirming the initial report of novel TP53 mutations in BRCA1-associated breast cancer. Over 80% of TP53 missense mutations reported to the database are in hot-spot codons. These hot-spot mutations abrogate wild-type p53 function, and the majority are located in important p53 structural domains. However, over a third of the BRCAassociated TP53 mutations were in non hot-spot codons. Computational modeling based on the solved p53 crystal structure found that a majority of these mutations were located outside these important structural domains.
p53 and BRCA1 are intimately linked in the DNA damage response through transcriptional regulation (MacLachlan et al., 2002) , common signaling pathways and protein stability (Xu et al., 2001b) . Given these interactions and the frequency with which novel BRCA-associated TP53 mutations are observed, the precise contribution of p53 to BRCA-associated tumorigenesis may be somewhat different from that occurring in tumors where the DNA damage response is less perturbed.
Haploinsufficient Brca1 and Brca2 mouse models
Lack of a phenotype in heterozygote knockout mice has been reported by most of the groups that attempted to derive null animals (Tables 4 and 5 ). However, the length of follow-up and the degree to which the heterozygote animals were examined varied. There have been no reports of tumor predisposition in animals followed through 1 -2 years of age. Attempts to induce tumor formation by cross-breeding with other mice and exposure to DNA-damaging agents have been performed. No tumors were detected 1 year after full-body irradiation of the Brca1 +/1700T mice as compared to wild-type controls. Crosses to p53 +/7 , p53 7/7 , Msh2 D7n and Apc 1638N mutant mice also revealed no difference in tumor incidence between wild-type and Brca1
1700T mice (Hohenstein et al., 2001 +/D223-763 mice, three of which had lost the wild-type Brca1 allele. No statistical significance could be ascertained due to the small sample size. All tumors had lost the wild-type p53 allele. In ENUtreated Apc Min/+ mice, a mouse line that is highly predisposed to developing mammary cancers, Brca1 heterozygosity had no effect on tumor incidence, latency, or multiplicity (Karabinis et al., 2001) . Although the repair of ENU-damaged DNA, which produces DNA base modifications without DSBs, may not be a particularly suitable model in which to examine the effects of Brca1 haploinsufficiency. Medina et al. (2002) employed a mammary transplant approach to examine the effects of p53 deficiency and Brca2 haploinsufficiency on tumor incidence and latency by transplantation of p53 null mammary cells on a BALB/c genetic background. As compared to Brca2 wild-type, Brca2 haploinsufficiency resulted in a modest increase in mammary tumor incidence in glands arising from p53 null transplanted mammary cells. A decrease in tumor latency was not observed (Medina et al., 2002) .
Mammary and reproductive tract development in Brca1 and Brca2 heterozygote mice were carefully analysed with and without DES exposure (Bennett et al., 2000b) . Subtle decreases were found in the complexity of mammary development in untreated Brca2 heterozygous mice as compared to wild-type mice. Following DES administration, similar differ- 
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Figure 3 A graphic depiction of gender specific cancer risk by age 70 in carriers of BRCA1 or BRCA2 mutations. The diagrams are representative of the risks reported from both population based and cancer family databases. Other cancers for BRCA1 female carriers include colon, gastric and pancreas, although the increases in these cancers are small and not uniformly observed. In male carriers of BRCA1 mutations, there is discrepancy as to if there is any increase in cancer risk, although in some studies small increases in breast, prostate and pancreas cancer are reported. A wider spectrum of cancer risk for carriers of BRCA2 is clearly seen in both males and females. Other cancers for BRCA2 carriers include stomach, melanoma and gall bladder ences with defects in ductal branching were seen in both Brca1 and Brca2 heterozygote mice. In addition, an increased incidence of ovarian follicular arrest in the heterozygote mice was noted. Mammary or ovary tumor development was not observed in the DEStreated mice.
BRCA1 and BRCA2 tumor suppression
In mice or humans, the loss of either BRCA1 or BRCA2 predisposes to tumorigenesis. In humans, the tissues at risk to develop tumors were initially thought to be restricted to mammary and ovary epithelium. For BRCA2, this is clearly not the case, although the penetrance of disease for breast and ovary cancer is not as high as for a carrier of a BRCA1 mutation (Begg, 2002) . Carriers of BRCA2 mutation have an increased risk of developing male breast cancer, pancreas cancer, gastrointestinal cancers and prostate cancer (Figure 3 ) (BCLC, 1999 ). An even broader tissue range of BRCA2-associated cancers has been reported in some cancer families, strongly suggesting the role of modifiers in the penetrance of BRCA2-associated disease. The cancer risk associated with BRCA1 germline mutation is less clear for tumors other than breast, ovary, and fallopian tube cancers (BCLC, 1999; Brose et al., 2002; Thompson and Easton, 2002) . Large studies have reported both a lack of association and small association with BRCA1 mutation in male breast and prostate cancer (Basham et al., 2002; Brose et al., 2002; Frank et al., 2002; Thompson and Easton, 2002) . A recent editorial commenting on reports from two large and overlapping databases brings to light the difficulties in estimating/establishing other small cancer risks due to BRCA1 mutation (Gruber and Petersen, 2002) . Additional differences between BRCA1 and BRCA2-associated cancers include gender-specific risk (Thompson and Easton, 2002) , average age at diagnosis (Risch et al., 2001) , and the effect of genetic modifiers on cancer risk (Levy-Lahad et al., 2001; Wang et al., 2001) . As compared to BRCA1 mutation carriers, BRCA2 mutation carriers present with disease at an older age and have an overall lower penetrance of cancer risk but are at risk of developing more types of cancer in both males and females.
BRCA1 and BRCA2-associated breast cancers are significantly distinct, from each other, by histology, IHA and gene expression profiles. It is less clear as to whether BRCA2 mammary tumors are significantly different from sporadic breast cancers, as pathology features are not dissimilar but differences in gene expression profiles have been reported. These differences underscore the complexity underlying BRCA1-associated cancers. Tumor suppression by BRCA1 may possibly be due to the interrelationship of defective DNA repair and an overall dysregulation of the DNA damage response, whereas BRCA2-deficiency results in a homologydirected DSB repair defect that may be attenuated by an overlapping function of other DSB repair pathways.
Certainties and uncertainties in BRCA-associated tumor suppression
Human BRCA1 breast cancers and Brca1 mammary tumor models have similar pathologic features, such as high tumor grade, hormone receptor negativity, a high incidence of p53 mutations and genetic instability. The recurring chromosome aberrations observed in the Brca1 mammary tumors mapped to chromosome regions and gene locations commonly altered in human breast cancer. The similarities between human BRCA2 breast cancer and reported murine Brca2 models are less apparent, although both are more likely to be hormone receptor positive, Her-2 negative and less genetically unstable as compared to BRCA1-associated tumors. The viable hypomorphic Brca1
Tr and Brca2-Dex27 mouse models sustain a wide spectrum of carcinomas. No gender difference as pertaining to tumor incidence was noted.
The observed pattern of multiple chromosome gains and losses and progressive genomic instability in Brca1-associated tumors is highly suggestive of Brca1 as a caretaker of the genome through DNA damage response and repair. Early genetic instability, long tumor latency and multiclonality support the hypothesis that loss of Brca1 promotes further genetic change, some of which provide additional growth advantages.
p53 is markedly cooperative with both Brca1 and Brca2 in tumor suppression of carcinoma. However, loss of p53 function does not appear to be required for tumorigenesis. Novel TP53 mutations identified in human breast cancer suggest that a significant proportion of the mutations may not abrogate most wild-type p53 functions, the clinical significance of these mutations in either tumorigenesis or tumor behavior is unknown.
Caretakers of the genome act as safeguards against genetic change during routine cellular metabolism and damage from external stresses. Several mechanisms have been attributed to the genetic instability found in BRCA1 deficiency and include defective DSB repair by the homologous repair pathway, defective DSB repair which may possibly result in an increase in the proportion of error prone repair events by NHEJ (reviewed in Jasin), defective G2-M checkpoint (Xu et al., 1999b (Xu et al., , 2000a Yarden et al., 2002) and centrosome abnormalities (Deng, 2002) . Does BRCA-associated tumorigenesis occur when all or only a subset of these functions are abrogated? Additional hypomorphic or conditionally deleted animal models that allow for a separation of function may help refine the role of BRCA1 and BRCA2 in tumor suppression.
